High-density lipoprotein (HDL)-mimicking peptide–phospholipid scaffold (HPPS) nanoparticles are used as a flexible and biocompatible nanocarrier for the delivery of small interfering RNA (siRNA). The direct cytosolic delivery ability of cholesterol-modified siRNA displayed by the nanoparticle results in the selective delivery of RNA interference (RNAi) to targeted cells. This provides a strategy to bypass endolysosomal trafficking, and makes HPPS a useful tool for therapeutic siRNA delivery.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: